# A Biomarker Screening Protocol for Participants With Solid Tumors

> **NCT05891197** · — · TERMINATED · sponsor: **Lyell Immunopharma, Inc.** · enrollment: 10 (actual)

## Conditions studied

- Triple Negative Breast Cancer
- Non-small Cell Lung Cancer
- Non Small Cell Lung Cancer
- Non Small Cell Lung Cancer Metastatic
- Non-Small Cell Carcinoma of Lung, TNM Stage 4
- Advanced Breast Cancer
- Advanced Lung Carcinoma
- NSCLC
- NSCLC, Recurrent
- NSCLC Stage IV
- Relapsed Cancer
- Relapse/Recurrence
- Recurrent Breast Cancer
- Recurrent NSCLC
- Platinum-resistant Ovarian Cancer
- Ovarian Cancer
- Primary Peritoneal Carcinoma
- Fallopian Tube Cancer
- Endometrial Cancer
- Endometrioid Tumor
- High Grade Serous Carcinoma
- Ovarian Epithelial Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05891197
- **Lead sponsor:** Lyell Immunopharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2023-05-19
- **Primary completion:** 2025-02-05
- **Final completion:** 2025-02-05
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Pipeline Reprioritization
- **Last updated:** 2025-07-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05891197

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05891197, "A Biomarker Screening Protocol for Participants With Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05891197. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*